March 21st 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses the efficacy and safety with teclistamab for patients with relapsed/refractory multiple myeloma.
Roundtable Discussion: Ailawadhi Compares Therapies in Newly Diagnosed Multiple MyelomaMarch 7th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Sikander Ailawadhi, MD, discussed with participants the choice of regimen for a patient with transplant-eligible newly diagnosed multiple myeloma.
FDA Grants Priority Review to BLA of Elranatamab for R/R Multiple MyelomaFebruary 22nd 2023
Results from cohort A of the MagnetisMM–3 trial of erlanatamab for patients with relapsed/refractory multiple myeloma have led the FDA to grant priority review to a biologics license application for the agent in this patient population.
Ide-Cel Induces PFS Benefit in Triple-Class-Exposed R/R Multiple MyelomaFebruary 19th 2023
A second interim analysis of the phase 3 Karmma-3 trial demonstrated significantly improved progression-free survival and overall response rates, compared with standard regimens, in patients with triple-class-exposed relapsed/refractory multiple myeloma.
Chronic Opioid Use After ASCT May Worsen OS in Multiple MyelomaFebruary 18th 2023
A single-center, retrospective study demonstrated high rates of chronic opioid use after autologous stem cell transplantation in patients with multiple myeloma, also leading to inferior overall survival at 6 months of follow-up.
Roundtable Roundup: Previously Untreated Multiple MyelomaFebruary 8th 2023
In separate live, virtual events, David Dingli, MD, PhD, and Douglas W. Sborov, MD, MS, discussed with participants how they would treat a patient with multiple myeloma in accordance with the available therapeutic regimens.
Real-World Data Shows Wider Reach for Ide-Cel in RRMMFebruary 5th 2023
After the results of the phase 2 KarMMa trial showed that idecabtagene vicleucel is a new standard of care in relapsed/refractory multiple myeloma, a real-world analysis continues to show the CAR T-cell therapy could have a wider reach.
Supportive Care for Maintenance in Transplant-Ineligible Multiple MyelomaFebruary 3rd 2023
During a Targeted Oncology case-based roundtable event, Amandeep Godara, MD, discussed the use of maintenance therapy for patients with multiple myeloma. This is the second of 2 articles based on this event.
Cilta-Cel May Lower Risk of Disease Progression or Death in R/R Multiple MyelomaJanuary 27th 2023
Cilta-cel improved progression-free survival in relapsed/refractory multiple myeloma, according to findings from the first prespecified interim analysis of the phase 3 CARTITUDE-4 study.
MoumenTAL-1: Management of Adverse Events and Health-Related Quality of Life OutcomesJanuary 25th 2023
Dr Peter Voorhees highlights MonumenTAL-1, discussing management of notable adverse events and health-related quality of life outcomes from patients with R/R multiple myeloma.
MonumenTAL-1 and Bispecifics Under Development for The Treatment of R/R Multiple MyelomaJanuary 25th 2023
Dr Peter Voorhees reviews bispecifics under development and updated outcomes data from the MonumenTAL-1 trial, evaluating talquetamab in patients with R/R multiple myeloma.
Case Presentation: A 63-Year-Old Patient with Relapsed-Refractory (R/R) Multiple MyelomaJanuary 25th 2023
Peter Voorhees, MD, presents a case of a 63-year-old man with R/R multiple myeloma, shares his initial impressions, and discusses the assessment of clinical relapse in patients with R/R multiple myeloma.
MRD Testing With Next-Generation Sequencing Can Guide Treatment of Multiple MyelomaJanuary 17th 2023
In an interview with Targeted Oncology, Gayathri Ravi, MD, further discussed findings from a presentation at ASH 2022, and the role of minimal residual disease testing in multiple myeloma.
Using MRD Negativity to Discontinue Maintenance Treatment in Multiple MyelomaJanuary 15th 2023
In an interview with Targeted Oncology, Ben Derman, MD, discussed data from an ongoing clinical trial evaluating MRD-guided discontinuation of maintenance therapy in patients with multiple myeloma.